February 2016

Immuno-Oncology 2016 and Beyond: The Opportunities, Challenges, and Risks

February 04, 2016

Evidence-Based Oncology

The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.

The Fight of Our Lives: Confronting the Unmet Need in Lung Cancer

February 05, 2016

Evidence-Based Oncology

Supporting, funding, and protecting the research and development of new medicines and new treatments is more critical, now than ever, to provide better treatments and better outcomes to all cancer patients.

Evolving Practices in Managing Costly Immunotherapy

February 08, 2016

Evidence-Based Oncology

To address the nationwide concern of costly immunotherapy agents, this article features health system inpatient and outpatient strategies that can help mitigate their costs.

Patient Assistance: Implementing Preventative Steps to Ensure Financial Wellness

February 10, 2016

Evidence-Based Oncology

An overview of patient assistance programs at Smilow Cancer Hospital at Yale-New Haven, including their innovative hospital-based explanation of benefits form, which can eliminate patient responsibilities and help expedite the turnaround times for payment processing with copay assistance.

Shaping the Future of Immuno-Oncology

February 11, 2016

Evidence-Based Oncology

While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.

Cancer MoonShot 2020 Proposes a Collaborative Precision Cancer Care Model

February 11, 2016

Evidence-Based Oncology

At the annual JP Morgan Healthcare Conference, Patrick Soon-Shiong, MD, introduced Cancer MoonShot, his vision for a coalition to improve cancer outcomes. His claims on federal support for the project, however, stirred some controversy.

FDA Update in Oncology, February 2016

February 12, 2016

Evidence-Based Oncology

Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.